Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Biotech Players Lead the Growth Charge in the Legal Cannabis Market

NetworkNewsWire Editorial Coverage


News provided by

NetworkNewsWire

27 Jul, 2017, 12:30 GMT

Share this article

Share toX

Share this article

Share toX

NEW YORK, July 27, 2017 /PRNewswire/ --

The backbone of medical advancement is biotechnology, an industry wrought with the incredible potential of novel drug R&D, but vulnerable to the risk of stringent regulatory approval processes. Within this volatile market, however, is the cannabis-biotech sub-sector - a market flourishing with opportunity, innovation, and deep roots of medical possibilities. Fueled by an increasing volume of supportive research, cannabis-based biotech companies are addressing large markets of unmet medical need while rising to meet global demand of epic proportion. Included among several companies in the cannabis-biotech sub-sector is Lexaria Bioscience Corp. (OTC: LXRP) (CSE: LXX.CN) (LXRP Profile), a company emerging as a recognizable name within a space occupied by companies like GW Pharmaceuticals PLC (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Insys Therapeutics, Inc. (NASDAQ: INSY) and Axim Biotechnologies Inc. (OTC: AXIM).

Because the cannabis-biotech sub-sector remains in relative infancy, it is full of uncharted territory and prospects as companies aggressively explore the medicinal potential of marijuana and the plant's compounds and applications. Food bioscience company Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX), for instance, enjoys a unique position in this sub-sector. As the only publicly traded company with a cannabis-based intellectual portfolio that includes NSAIDs, nicotine and vitamins, Lexaria has multiple patents pending in over 40 countries, and it recently received its first patents in the U.S. and Australia relating to edible forms of cannabinoids (http://nnw.fm/e8LvY).

At the center of these patents is the company's proprietary technology, which improves the delivery of bioactive compounds, primarily cannabinoids, into the human body. While cannabinoids tout great potential for medical treatment, the compounds are poorly absorbed by the gastrointestinal tract. As a result, users frequently turn to alternative administration methods, like smoking, for enhanced effectiveness. Lexaria's lipophilic enhancement technology, however, demonstrates the ability to boost bioavailability of orally-ingested cannabinoids while at the same time masking their 'unusual' taste. This technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids. Other patents are also pending for tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

In collaboration with the National Research Council of Canada ('NRC') (http://nnw.fm/fdG8Z), Lexaria has commenced lab work to study and optimize the application of its technology toward enabling the delivery of lipophilic active agents within foods, beverages, capsules and other ingestible formats. Practical applications of this collaboration could include expansion of Lexaria's IP portfolio and the possibility of new commercial arrangements. Lexaria currently has two distinct consumer brands that utilize this game-changing technology of infusing hemp oil inside the lipids in foods: ViPova™ and Lexaria Energy.

Introduced in 2015, the ViPova product line began with a Chinese black tea containing hemp oil infused into dried, evaporated nonfat milk. The following year, Lexaria took advantage of the broader beverage market, and ViPova's product line was expanded to include coffee and hot chocolate. The company sells its ViPova product directly online to consumers.

Lexaria Energy products also utilize the company's patented infusion technology to deliver federally legal hemp oil ingredients inside nutritious and tasty formulations that are free of the bitter taste typically associated with hemp. Products in this line include the Lexaria Energy Bar, a hemp oil-infused protein bar. Other nutritious products are in development for the Lexaria Energy line, with a focus on ensuring responsible production techniques and gluten-free formulations.

Lexaria also licenses its technology to third-party partners, making royalties an integral part of its overall business strategy and revenue potential as it pursues opportunities to broaden and strengthen its IP portfolio. Because Lexaria's technology relies on a delivery methodology - and not just a single drug or molecule - even cannabis giants like GW Pharmaceuticals PLC (NASDAQ: GWPH) might discover Lexaria's technology as an effective way to deliver its drug.

GW Pharmaceuticals has become a world leader in developing plant-derived cannabinoid therapeutics by leveraging its established drug discovery and development processes, extensive intellectual property portfolio, and regulatory and manufacturing expertise. The company's research delves into the potential therapeutic applications of cannabinoids, and GW has evaluated the pharmacology of various cannabinoids across a broad array of disease areas. GW's focus is chiefly on central nervous system disorders, including epilepsy. The company's lead product candidate, Epidiolex, is a liquid formulation of pure plant-derived CBD and is in development to treat various rare childhood-onset epilepsy disorders. GW has also commercialized Sativex, the world's very first plant-derived cannabinoid prescription drug, which has been approved in 29 countries outside the U.S. for the treatment of multiple sclerosis-related spasticity. GW's pipeline of other cannabinoid product candidates includes compounds in development for treating epilepsy, glioma and schizophrenia.

Another biotech standout in the cannabis market is clinical-stage pharmaceutical company Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE). Zynerba is focused on the development of innovative transdermal synthetic cannabinoid treatment options for patients with high unmet medical needs. The company's development pipeline includes two lead product candidates that are being evaluated in five therapeutic indications: ZYN002 and ZYN001. Currently in phase 2 clinical development for refractory epilepsy, osteoarthritis of the knee and Fragile X syndrome, ZYN002 is the first and only synthetic form of CBD and has been formulated as a patent-protected permeation-enhanced gel for transdermal delivery into the circulatory system. ZYN001 is a THC pro-drug that enables transdermal delivery through the skin and into the circulatory system via a patch. A phase 1 clinical program for fibromyalgia and peripheral neuropathic pain was initiated by Zynerba in the first half of 2017.

Specialty pharmaceutical company Insys Therapeutics, Inc. (NASDAQ: INSY) is focused on developing and commercializing innovative drugs and novel drug delivery systems for therapeutic molecules with the end goal of improving quality of life for patients. Insys uses proprietary sublingual spray technology along with its pharmaceutical cannabinoid development capabilities to address the clinical inadequacies of existing commercial products. In May 2017, Insys Therapeutics received FDA approval for the final product label of its Syndros (dronabinol) oral solution, marking the last regulatory step needed before the official launch of the product, which is planned to take place sometime in August 2017. Syndros is a liquid formulation of the pharmaceutical cannabinoid dronabinol and has been approved for use in the treatment of weight loss-related anorexia in AIDS patients and nausea and vomiting in chemotherapy patients who are unresponsive to conventional antiemetic treatments. Insys is additionally at the phase 2 clinical development stage for a cannabidiol treatment to address severe pediatric epilepsies.

Biotechnology company Axim Biotechnologies Inc. (OTCQB: AXIM) is a leader in cannabinoid R&D and is striving to set the green standard for cannabinoid bioscience. The company's most advanced program is its phase 2 clinical trial of CanChew Plus chewing gum to treat irritable bowel syndrome. The company is similarly using a chewing gum-based approach for the treatment of pain, multiple sclerosis spasticity and other indications. CanChew Gum is the world's first patented, functional chewing gum that is derived from CBD-rich industrial hemp, and it is legal in all 50 states. Axim is additionally conducting research into the use of molecularly-modified cannabinoids as neuroprotectants, as well as the use of industrial hemp-derived formulations of cannabigerol (CBG) for dermatological applications. AXIM is further conducting trials or has products in development targeting a large number of indications, including ADHD, smoking cessation, ulcerative colitis, Crohn's disease, drug-related psychosis, psoriasis, atopic dermatitis and more. The company is also in the process of developing a unique extraction and freeze-drying technology for producing molecularly/genetically-controlled pharma-grade cannabinoids extracted from industrial hemp.

For biotech investors looking at the legal cannabis sector and interested in potentially taking part of the growth in the broader marijuana industry, the companies described above are all worth keeping on your investment radar. Stay tuned to NetworkNewsWire for more public information on investment opportunities and on Lexaria Bioscience.  

For more information on Lexaria Bioscience, please visit: Lexaria Bioscience Corp. (LXRP)

About NetworkNewsWire  

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.

NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW and FNM undertake no obligation to update such statements.

Media Contact e-mail:
FN Media Group, LLC
editor@financialnewsmedia.com
+1(954)345-0611

Modal title

Also from this source

Near-Term Production Assets Gain Traction amid Historic Gold Price Surge

Near-Term Production Assets Gain Traction amid Historic Gold Price Surge

Gold's remarkable surge — driven by an unstable U.S. fiscal policy and rising inflation — has propelled prices beyond the historic US$3,300 per ounce ...

From Exploration to Execution: New Gold Player Emerges in One of Canada's Premier Mining Districts

From Exploration to Execution: New Gold Player Emerges in One of Canada's Premier Mining Districts

Gold's meteoric rally, fueled by waning confidence in U.S. fiscal policy and soaring inflation, has not only pushed prices past the historic US$3,300 ...

More Releases From This Source

Explore

Biotechnology

Biotechnology

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.